Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spyre Therapeutics
Biotech
Spyre touts ph. 2 UC win as proof it could surpass Entyvio
Spyre’s monoclonal antibody hit the key goal in a phase 2 study for ulcerative colitis, which the company touted as proof it can best Takeda’s Entyvio.
James Waldron
Apr 13, 2026 9:55am
BMS snags top neuro researcher from Eisai—Chutes & Ladders
Jan 23, 2026 8:30am
Prothena promotes one exec while another leaves—Chutes & Ladders
Oct 4, 2024 8:00am
FDA promotes Bumpus to replace Woodcock—Chutes & Ladders
Dec 1, 2023 9:48am
Aeglea scoops up Spyre to stay afloat
Jun 22, 2023 10:50am
